MVI Logo

Relevant Literature from the McNeel Laboratory

Technology discovered and initially translated in the laboratory of Douglas McNeel, M.D., Ph.D. underpin the science and clinical development strategies of MVI. Dr. McNeel and collaborating scientists have published their work in peer-reviewed journals and written reviews on DNA vaccines and tumor immunotherapy. A sample bibliography is listed below.

 

Prostatic Acid Phosphatase Vaccine and Immunology

 

Johnson LE and McNeel DG.  (2012)  “Identification of prostatic acid phosphatase (PAP) specific HLA-DR1-restricted T-cell epitopes.”  Prostate  72:730-740.  (PMID: 22529020)

 

Becker JT, Olson BM, Johnson LE, Davies JG, Dunphy EJ, and McNeel DG.  (2010)  “DNA vaccine encoding prostatic acid phosphatase (PAP) elicits long-term T-cell responses in patients with recurrent prostate cancer.”  J Immunotherapy 33:639-647.  (PMID 20153396, PMCID: PMC3045767).

 

Olson BM, Frye TP, Johnson LD, Fong L, Knutson KL, Disis ML, and McNeel DG.  (2010) “HLA-A2-restricted T-cell epitopes specific for prostatic acid phosphatase.”  Cancer Immunol. Immunother.  59:943-953.  (PMID 20140431, PMCID: PMC3038205)

 

McNeel DG, Dunphy EJ, Davies JG, Frye TP, Johnson LE, Staab MJ, Horvath DL, Straus J, Alberti D, Marnocha R, Liu G, Eickhoff JC, and Wilding G.  (2009)  “Safety and immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase (PAP) in patients with stage D0 prostate cancer.” J. Clin. Oncol. 27:4047-4054.  (PMID: 19636017, PMCID:  PMC2734418)

 

Johnson LE, Frye TP, Chinnasamy D, Chinnasamy N, and McNeel DG.  (2007)  “Plasmid DNA vaccine encoding prostatic acid phosphatase (PAP) effective in eliciting autologous antigen-specific CD8 T cells.”  Cancer Immunol Immunother  56:885-895.  (PMID:  17102977)

 

Johnson LE, Frye TP, Arnot AR, Marquette C, Couture LA, Gendron-Fitzpatrick A, and McNeel DG.  (2006)  “Safety and immunological efficacy of a prostate cancer plasmid DNA vaccine encoding prostatic acid phosphatase (PAP).”  Vaccine 24:293-303.  (PMID:  16115700)

 

McNeel DG, Nguyen LD and Disis ML.  (2001)  “Identification of T helper epitopes derived from prostatic acid phosphatase.”  Cancer Res. 61:5161-5167.  (PMID:  11431355)

 

 

Androgen Receptor Vaccine and Immunology

 

Olson BM, Johnson LE, and McNeel DG.  (2013)  “The androgen receptor – a biologically-relevant vaccine target for the treatment of prostate cancer.”  Cancer Immunol. Immunoth.  62:585-596.  (PMID: 23108626, PMD)

 

Olson BM and McNeel DG.  (2011)  “CD8+ T cells specific for the androgen receptor are common in patients with prostate cancer and are able to lyse prostate tumor cells.”  Cancer Immunol. Immunoth.  60:781-792.  (PMID: 21350948, PMCID: PMC3319721).

 

Olson BM and McNeel DG.  (2007)  “Antibody and T-cell responses specific for the androgen receptor in patients with prostate cancer.”  Prostate 67:1729-1739.  (PMID:  17879963)

 

 

Antigen-specific CD8+ Regulatory T-cells

 

Olson BM, Jankowska-Gan E, Becker JT, Vignali DAA, Burlingham WJ, and McNeel DG.  (2012)  “Human prostate tumor antigen-specific CD8+ regulatory T cells are inhibited by CTLA-4 or IL-35 blockade.”  J. Immunol.  189:5590-5601.  (PMID: 23152566, PMCID)

 

 

Selected Invited Review Articles

 

Colluru VT, Johnson LE, Olson BM, and McNeel DG.  (2013)  “Preclinical and clinical development of DNA vaccines for prostate cancer.”  Urol. Oncol. (in press).

 

Olson BM and McNeel DG.  (2013)  “Monitoring regulatory immune responses in tumor immunotherapy clinical trials.”  Front. Oncol.  3:1-11.

 

McNeel DG, Becker JT, Johnson LE, and Olson BM.  (2012)  “DNA vaccines for prostate cancer.”  Curr. Cancer Ther. Rev. 8:245-253.

 

Alam S and McNeel DG(2010)  “DNA vaccines for the treatment of prostate cancer.”  Exp. Rev. Vaccines  9:731-745.  (PMID: 20624047)

 

Kipp RT and McNeel DG.  (2007)  “Immunotherapy of prostate cancer.”  Clin. Adv. Hem. Onc.  5:465-479.  (PMID:  17679921)